Nestle Health Science gets license to Lipid Therapeutics' Phase III UC candidate
Executive Summary
Lipid Therapeutics GMBH licensed Nestle Health Science SA exclusive worldwide rights (excluding Europe and Australia) to its Phase III LT02 (phosphatidylcholine) for mild-to-moderate ulcerative colitis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice